Literature DB >> 21834061

Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors.

Meliha Crnkic Kapetanovic1, Carmen Roseman, Göran Jönsson, Lennart Truedsson, Tore Saxne, Pierre Geborek.   

Abstract

OBJECTIVE: To study the influence of antiinflammatory treatments, including methotrexate (MTX) and tumor necrosis factor (TNF) inhibitors, on antibody response following vaccination using a 7-valent conjugate pneumococcal vaccine in adult patients with established arthritis.
METHODS: Patients with rheumatoid arthritis (RA) or spondylarthropathy (SpA) (including psoriatic arthritis) were vaccinated (n = 505). All patients were stratified into 6 prespecified groups based on diagnosis and treatment (RA patients receiving MTX, RA patients receiving anti-TNF agents and MTX, RA patients receiving TNF inhibitors as monotherapy, SpA patients receiving anti-TNF agents and MTX, SpA patients receiving TNF inhibitors as monotherapy, and SpA patients receiving nonsteroidal antiinflammatory drugs [NSAIDs] and/or analgesics). SpA patients receiving only NSAIDs/analgesics served as a control group. All patients received 1 dose (0.5 ml) of vaccine intramuscularly. Levels of IgG antibodies against 23F and 6B serotypes were measured at vaccination and at 4-6 weeks following vaccination, using standardized enzyme-linked immunosorbent assays.
RESULTS: Positive antibody response was defined as an antibody response ratio (ARR) (i.e., ratio of post- to prevaccination antibody levels) of ≥2. The ARR differed significantly between the groups. A better ARR was seen among patients in the control group compared to those in groups treated with MTX or MTX in combination with TNF inhibitors. Among patients treated with TNF inhibitors as monotherapy, ARRs for both serotypes were lower numerically, but were not significantly different, compared to those in controls. Ongoing MTX treatment was predictive of reduced response (odds ratio 0.41 [95% confidence interval 0.24-0.68], P = 0.001). Higher age was associated with impaired positive antibody response. Concomitant prednisolone treatment elicited better positive antibody response in patients with RA.
CONCLUSION: Treatment with MTX and higher age were predictive of an impaired antibody response to the 7-valent conjugate pneumococcal vaccine in this cohort of patients with chronic arthritis. TNF inhibitors did not significantly affect antibody responses.
Copyright © 2011 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21834061     DOI: 10.1002/art.30580

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  49 in total

1.  Heptavalent pneumococcal conjugate vaccine elicits similar antibody response as standard 23-valent polysaccharide vaccine in adult patients with RA treated with immunomodulating drugs.

Authors:  Meliha Crnkic Kapetanovic; Carmen Roseman; Göran Jönsson; Lennart Truedsson
Journal:  Clin Rheumatol       Date:  2011-09-29       Impact factor: 2.980

Review 2.  A literature review on the patients with autoimmune diseases following vaccination against infections.

Authors:  Yan Liang; Fan-Ya Meng; Hai-Feng Pan; Dong-Qing Ye
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  QuantiFERON testing for cell-mediated immunity to cytomegalovirus in patients with rheumatoid arthritis receiving abatacept and other DMARD therapy.

Authors:  Anthony S Russell; Luiz Lisboa; Marla F Dos Santos; Deepali Kumar; Atul Humar
Journal:  Clin Rheumatol       Date:  2013-06-11       Impact factor: 2.980

4.  [Pneumococcus vaccination in immunosuppressed patients: current recommendations].

Authors:  A Krause; K Krüger
Journal:  Z Rheumatol       Date:  2013-12       Impact factor: 1.372

Review 5.  Defining quality indicators for best-practice management of inflammatory bowel disease in Canada.

Authors:  Geoffrey C Nguyen; Shane M Devlin; Waqqas Afif; Brian Bressler; Steven E Gruchy; Gilaad G Kaplan; Liliana Oliveira; Sophie Plamondon; Cynthia H Seow; Chadwick Williams; Karen Wong; Brian M Yan; Jennifer Jones
Journal:  Can J Gastroenterol Hepatol       Date:  2014-05

6.  Immunogenicity and persistence of a prime-boost re-vaccination strategy for pneumococcal vaccines in patients with rheumatoid arthritis.

Authors:  Mathilde Bahuaud; Constance Beaudouin-Bazire; Marine Husson; Anna Molto; Odile Launay; Frédéric Batteux; Maxime Dougados
Journal:  Hum Vaccin Immunother       Date:  2018-04-09       Impact factor: 3.452

Review 7.  Adverse reactions to biologic agents and their medical management.

Authors:  Onur Boyman; Denis Comte; François Spertini
Journal:  Nat Rev Rheumatol       Date:  2014-08-12       Impact factor: 20.543

8.  Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis.

Authors:  Meliha C Kapetanovic; Lars-Erik Kristensen; Tore Saxne; Teodora Aktas; Andreas Mörner; Pierre Geborek
Journal:  Arthritis Res Ther       Date:  2014-01-02       Impact factor: 5.156

Review 9.  Vaccinations for rheumatoid arthritis.

Authors:  Lisa M Perry; Kevin L Winthrop; Jeffrey R Curtis
Journal:  Curr Rheumatol Rep       Date:  2014-08       Impact factor: 4.592

Review 10.  Vaccination of patients with autoimmune inflammatory rheumatic diseases.

Authors:  Johanna Westra; Christien Rondaan; Sander van Assen; Marc Bijl
Journal:  Nat Rev Rheumatol       Date:  2014-12-09       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.